Hoth Therapeutics Inc. recently announced the granting of Japan Country Patent No. 7677628 for its HT-KIT platform. This patent provides protection until August 27, 2039, securing long-term commercial exclusivity. The HT-KIT platform employs splice-switching oligonucleotides to selectively target and disrupt KIT gene expression in mast cells, which are involved in various inflammatory and oncologic conditions. This patent marks a significant step in the global development strategy of HT-KIT, particularly in the Asian market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。